We are
bright.
hopeful.
human.
driven.
Omniscope.
The future of diagnostics is here.
See what your immune system is seeing.
One universal diagnostic tool.
One universal diagnostic tool.
It all started with a shift of mindset.
Omniscope was founded in 2020 in response to the global pandemic by a group of scientists who wanted to be of service to humanity at a critical moment for our species. Together, we seek to apply our expertise for immediate impact.
We observed that “modern” medicine was using diagnostic tools that tend to be too narrowly focused - looking only at one disease at a time or focused on specific DNA sequence variations - resulting in diagnostic journeys of time-consuming guesswork. Frustrated that many groundbreaking scientific discoveries stayed in the scientific community instead of helping patients, we were called to find ways to put science in service of humanity and ensure cutting-edge science was accessible to all.
What emerged from these passionate conversations was a universal diagnostic and therapeutic to bring our humanistic vision of health equity to life.
Dr. Holger leads the Single Cell Genomics Group at the Spanish National Centre for Genomic Analysis (one of Europe’s largest Genome Centres). He has co-authored over 80 publications, and his research has received over €7.5m funding from (inter)national agencies. Dr. Holger is a key opinion leader in the field of Genomics, a member of the Human Cell Atlas project and a partner of the LifeTime Initiative.
Vijay views technology as fundamental to humanity. He has been part of scaling companies such as Illumina and 10X Genomics. He has acquired and commercialised disruptive diagnostic technologies during his leadership at Siemens Healthineers and Meridian Biosciences. Vijay has been part of important IPOs in the biotechnology industry and finds his passion in improving health by the application of technology.
Lynnette brings to Omniscope her experience in the financial sector, where she served a diverse client base at Aberdeen Asset Management. These spanned government, private and public financial institutions including Sovereign Wealth Funds, Global Pensions, Central Banks, Insurers as well as Independent intermediates, global banks and online fund platforms.
Matthew wrote his first program on a 1982 BBC Micro Model B at the age of 4. After more than 20 years of working in all aspects of software, in both startups and multinationals, across a wide spectrum of industries ranging from warehouse robotics to hedge funds, Matthew is still as excited about tech today as he was back then.
Preclinical and Translational Research program Director at the Vall d'Hebron Institute of Oncology (VHIO) within the Vall d'Hebron Hospital, Barcelona, Spain, since 2011. In 1998, he obtained his PhD from the University of Barcelona and joined the Memorial Sloan-Kettering Cancer Center (MSKCC) in New York as a post-doctoral fellow (first as a Research Fellow and then Research Associate since 2001). He was appointed ICREA Professor in 2004 and joined VHIO. In 2008, he was the recipient of a European Research Council (ERC) grant, became Board member of the European Association of Cancer Research (EACR) and Professor at Universitat Autònoma de Barcelona. In 2012, he founded Mosaic Biomedicals as a spin-off company from his lab. In 2016, he became Secretary General of the EACR.
Dr. Heyn leads the Single Cell Genomics Group at the Spanish National Centre for Genomic Analysis (one of Europe’s largest Genome Centres). He has co-authored over 80 publications, and his research has received over €7.5m funding from (inter)national agencies. Dr. Heyn is a key opinion leader in the field of Genomics, a member of the Human Cell Atlas project and a partner of the LifeTime Initiative.
Dr. Heyn leads the Single Cell Genomics Group at the Spanish National Centre for Genomic Analysis (one of Europe’s largest Genome Centres). He has co-authored over 80 publications, and his research has received over €7.5m funding from (inter)national agencies. Dr. Heyn is a key opinion leader in the field of Genomics, a member of the Human Cell Atlas project and a partner of the LifeTime Initiative.
Romain is a commercial executive with a passion for healthcare. Over the last 20 years, he held different international leadership positions at Siemens Healthineers and Erba Mannheim. He brings to Omniscope a wealth of expertise in product commercialization for in-vitro diagnostics markets and business development in emerging countries.
Romain is a commercial executive with a passion for healthcare. Over the last 20 years, he held different international leadership positions at Siemens Healthineers and Erba Mannheim. He brings to Omniscope a wealth of expertise in product commercialization for in-vitro diagnostics markets and business development in emerging countries.
Dr. Heyn leads the Single Cell Genomics Group at the Spanish National Centre for Genomic Analysis (one of Europe’s largest Genome Centres). He has co-authored over 80 publications, and his research has received over €7.5m funding from (inter)national agencies. Dr. Heyn is a key opinion leader in the field of Genomics, a member of the Human Cell Atlas project and a partner of the LifeTime Initiative.
Dr. Heyn leads the Single Cell Genomics Group at the Spanish National Centre for Genomic Analysis (one of Europe’s largest Genome Centres). He has co-authored over 80 publications, and his research has received over €7.5m funding from (inter)national agencies. Dr. Heyn is a key opinion leader in the field of Genomics, a member of the Human Cell Atlas project and a partner of the LifeTime Initiative.
Dr. Heyn leads the Single Cell Genomics Group at the Spanish National Centre for Genomic Analysis (one of Europe’s largest Genome Centres). He has co-authored over 80 publications, and his research has received over €7.5m funding from (inter)national agencies. Dr. Heyn is a key opinion leader in the field of Genomics, a member of the Human Cell Atlas project and a partner of the LifeTime Initiative.
Romain is a commercial executive with a passion for healthcare. Over the last 20 years, he held different international leadership positions at Siemens Healthineers and Erba Mannheim. He brings to Omniscope a wealth of expertise in product commercialization for in-vitro diagnostics markets and business development in emerging countries.
We strive to create an ecosystem that improves people's lives.
Get In Touch230, 230 Works Business Centre Second Floor
Eucharistic Congress Road
Mosta, MST 9039, Malta
Parc Científic de Barcelona
Cluster II - Floor 3
Avenida Doctor Marañon, 8
08028 Barcelona, Spain
3175 Hanover Street
Palo Alto, CA
94304-1130, USA
